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Background: Tuberculosis remains an important health concern in many countries. The aim of this study was to
identify predictors of unfavorable outcomes at the end of treatment (EOT) and at the end of study (EOS; 40 months
after EOT) in South Korea.
Methods: New or previously treated tuberculosis patients were recruited into a prospective observational cohort
study at two hospitals in South Korea. To identify predictors of unfavorable outcomes at EOT and EOS, logistic
regression analysis was performed.
Results: The proportion of multidrug-resistant tuberculosis (MDR-TB) was 8.2% in new cases and 57.9% in previously
treated cases. Of new cases, 68.6% were cured, as were 40.7% of previously treated cases. At EOT, diabetes, ≥3 previous
TB episodes, ≥1 significant regimen change, and MDR-TB were significantly associated with treatment failure or death.
At EOS, age ≥35, body-mass index (BMI) <18.5, diabetes, and MDR-TB were significantly associated with treatment
failure, death, or relapse. Among cases that were cured at EOT, age ≥50 and a BMI <18.5 were associated with subsequent
death or relapse during follow-up to EOS. Treatment interruption was associated with service sector employees or
laborers, bilateral lesions on chest X-ray, and previous treatment failure or treatment interruption history.
Conclusions: Risk factors for poor treatment outcomes at EOT and EOS include both patient factors (diabetes status, age,
BMI) and disease factors (history of multiple previous treatment episodes, MDR-TB). In this longitudinal, observational
cohort study, diabetes mellitus and MDR-TB were risk factors for poor treatment outcomes and relapse. Measures to
help ensure that the first tuberculosis treatment episode is also the last one may improve treatment outcomes.
Trial registration: ClinicalTrials.gov ID: NCT00341601 registered on June 19, 2006
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South KoreaBackground
Tuberculosis (TB), a global concern for both developing
and developed countries, has recently become more
complex due to increasing levels of drug resistance and
HIV co-infection [1]. Asian and African countries share
the highest burden of tuberculosis, accounting for about* Correspondence: raycho@yonsei.kr
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unless otherwise stated.85% of the 8.6 million newly diagnosed TB cases re-
ported globally in 2012 [2]. Efforts to reduce disease
burden have been largely focused on improving treat-
ment and diagnosis of patients with active disease [3].
Although HIV co-infection and multidrug-resistant
(MDR) TB are major contributors to the global TB epi-
demic [4], a deeper understanding of other risk factors
for poor outcome can suggest interventions that might
help reduce morbidity and mortality. Poor socioeco-
nomic status, including poverty, lack of education, and
urbanization are known risk factors for active tuberculosisd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Comparisons of baseline characteristics by new or previously treated cases (n = 669)
Variables Group (%) P-
valueNew case Previously treated case
Demographic
Gender Female 36 (16.1) 70 (15.7) 0.909
Male 188 (83.9) 375 (84.3)
Age 20-34 47 (21.0) 122 (27.4) 0.158
35-49 95 (42.4) 183 (41.1)
50- 82 (36.6) 140 (31.5)
Health condition
BMI (n = 626) <18.5 108 (50.2) 204 (49.6) 0.887
18.5- 107 (49.8) 207 (50.4)
Diabetes No 180 (80.4) 340 (76.4) 0.246
Yes 44 (19.6) 105 (23.6)
Individual behavior
Alcohol, within 6 months Less than once a week 102 (45.5) 245 (55.1) 0.062
Several times a week 39 (17.4) 68 (15.3)
At least once a day 83 (37.1) 132 (29.7)
Smoking, within 6 months Never smoked 56 (25.0) 125 (28.1) <0.001
< 1 pack/day 30 (12.39) 125 (28.1)
1 pack/day 78 (34.8) 121 (27.2)
> 1 pack/day 60 (26.8) 74 (16.6)
Socioeconomic
Residential area Small city and town 135 (60.3) 245 (55.1) 0.199
Large city 89 (39.7) 200 (44.9)
Education High school, above 120 (53.6) 251 (56.4) 0.487
Middle school, below and refusal 104 (46.4) 194 (43.6)
Occupation Health care, professional, office work 16 (7.1) 55 (12.4) 0.117
Service sector and laborer in construction
or factory
128 (57.1) 242 (54.4)
Unemployment and others 80 (35.7) 148 (33.3)
Housing status (n = 668) Private 201 (89.7) 415 (93.5) 0.089
Other 23 (10.3) 29 (6.5)
Tuberculosis-related clinical
Chest X ray
Grade Minimal 10 (4.5) 9 (2.0) 0.020
Moderately advanced 111 (49.6) 187 (42.0)
Far advanced 103 (46.0) 249 (56.0)
Cavity Yes 138 (61.6) 281 (63.1) <0.001
No 68 (30.4) 78 (17.5)
Not clear 18 (8.0) 86 (19.3)
Bilateral Unilateral 57 (25.4) 56 (12.6) <0.001
Bilateral 167 (74.6) 389 (87.4)
Nodular lesion Yes 199 (88.8) 417 (93.7) 0.038*
No 22 (9.8) 27 (6.1)
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Table 1 Comparisons of baseline characteristics by new or previously treated cases (n = 669) (Continued)
Not clear 3 (1.3) 1 (0.2)
Treatment History
Number of previous treatment episode (n = 444) 1 - 151 (33.9) -
2 - 106 (23.8)
3 - 63 (14.2)
4 or more - 125 (28.1)
Cumulative duration of previous treatment (days, n = 444) Median (IQR) - 304 (61-761) -
History of failure (n = 445) No - 249 (56.0) -
Yes - 196 (44.0)
History of treatment interruption (n = 445) No - 207 (46.5) -
Yes - 238 (53.5)
Drug Susceptibility pattern (n = 581) DS 146 (75.0) 92 (26.5) <0.001*
Mono/Poly-R 29 (14.8) 44 (11.4)
Rif, mono-R 4 (2.0) 16 (4.2)
MDR 16 (8.2) 223 (57.9)
AFB smear score at baseline
- 1 (0.5) 4 (0.9) 0.689*
Scant 51 (22.8) 85 (19.1)
1+ 121 (54.0) 247 (55.5)
≥2+ 51 (22.8) 109 (24.5)
*Tested by Fisher’s exact test.
BMI: Body mass index; DS: Drug susceptible, Mono/poly-R: mono or poly-drug resistance that is not matched with the definition of Multidrug-resistant tuberculosis;
MDR: multidrug-resistant tuberculosis.
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consumption and drug use are also associated with
poor treatment outcomes [7-10]. Clinical character-
istics including diabetes, baseline disease severity (on
chest X-ray), previous treatment history, and drug-
resistance have all been shown to be independent risk fac-
tors for poor treatment outcomes in previous studies
[11-13].
Few studies have prospectively identified factors
associated with long-term prognosis. A retrospective
study by Kim et al [14] evaluated long-term prognos-
tic factors among MDR-TB patients and found that
having extensively drug resistant (XDR) TB was the
strongest predictor of poor outcomes. Two other
studies evaluated the characteristics of patients with
tuberculosis relapse after treatment completion [15,16]. In
one, a prior history of TB treatment was the largest
risk factor associated with TB recurrence (HR: 5.2, CI:
1.7-16.2) [16] and, in another, DNA fingerprinting of
cases of recurrent TB suggested that those previously
infected with TB are at increased risk of developing TB
again when re-infected [15]. This study aims to identify
predictors with unfavorable outcome at the end of therapy
and the long-term unfavorable outcome after treatment
completion in South Korea.Methods
Study population and design
Subjects in this study were recruited prospectively into
an observational cohort study at the National Masan
Tuberculosis Hospital and the National Medical Center
in South Korea (ClinicalTrials.gov ID: NCT00341601).
Both new and previously treated tuberculosis cases
[defined according to World Health Organization (WHO)
definitions] [17] were enrolled in this study. The inclusion
criteria allowed enrollment of adults 20 years or older who
had clinical signs or symptoms suggestive of TB, and had
either a positive sputum smear for acid-fast bacilli or con-
firmed Mycobacterium tuberculosis in their sputum using
any molecular method. In addition, new cases could not
have had a treatment interruption lasting more than 60 days
and must have had at least 4 months of treatment
remaining in their current episode of TB. Previously
treated cases must either have previously been treated for
more than 30 days followed by a treatment interruption of
at least 60 days or have had a history of treatment failure
or chronic tuberculosis.
According to Korean tuberculosis guidelines [18], drug-
resistant TB patients are treated with an individualized
regimen based on results of drug-susceptibility testing.
For drug-susceptible and new patients, hospital guidelines
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cases with minimal disease that are initially sputum smear
and culture negative. In this study, regular follow-up was
conducted by medical chart abstraction or phone call at 3
to 6 month intervals; the final follow-up was performed
up to 40 months after treatment completion. Data col-
lected from 2005-2012 are included in this study.
Measurements and definitions
Treatment outcomes were categorized as cure, failure,
treatment interruption, unknown, death, relapse or with-
drawal and were assessed at both the end of treatment
(EOT) and the end of study (EOS) follow-up phone call.
Treatment outcomes at EOT were defined as follows: a)
cure was defined as a patient who was initially sputum
smear-positive and who was sputum smear-negative in
the last month of treatment and on at least one previous
occasion, per the WHO Global Tuberculosis Report 2013
[2]; b) failure was defined as 6-month sputum culture
positivity for drug-susceptible (DS) cases and treatment
termination or need for permanent regimen change of at
least two anti-TB drugs for rifampin-resistant (RR) andTable 2 Comparisons of treatment-course related characterist
previously treated status (n = 669)
Variables (n) New cas
Number of significant regimen change
0 194 (86.6
≥1 30 (13.4
Elevation of total bilirubin
No 143 (63.8
Yes 81 (36.2
Elevation of liver enzyme
No 181 (80.8
Yes 43 (19.2
Months to treatment completion, median (IQR) 9.45 (8.89-1
Treatment outcome at EOT
Cured 154 (68.8
Failure 4 (1.8)
TI 35 (15.6
Unknown 15 (6.7)
Death 6 (2.7)
Withdrawal 10 (4.5)
Culture positivity (since enrollment)
Converted prior to 6 months 145 (64.7
Positivity at 6 months, over 14 (6.2)
Unknown 6 month result 65 (29.0
Months to TI, median (IQR) 7.98 (5.02-1
*Tested by Fisher’s exact test.
† Tested by Mann-Whitney test.
AFB: Acid fast bacilli; IQR: Interquartile range; EOT: End of therapy; TI: Treatment intMDR cases; c) treatment interruption (TI) was defined as
voluntary cessation of therapy for 2 or more consecutive
months without restarting the same regimen within
6 months; d) death was defined as a case who died for any
reason during the treatment course; e) unknown was de-
fined as a case whose treatment outcome was not known,
including loss to follow-up and lack of microbiologic in-
formation at EOT; f) withdrawal was defined as a case
who withdrew from the study before treatment completion.
Treatment outcomes at EOS were assessed approximately
40 months after treatment completion as follows: i) cure
was defined as a case who was cured at EOT and com-
pleted the study without relapse, death, or withdrawal; ii)
failure was defined as culture positivity 2 years after treat-
ment initiation, regardless of drug-resistance; iii) death was
defined as a case who died for any reason during the entire
study period; iv) relapse was defined as a case who
reinitiated TB treatment after being designated a cure
at treatment completion.
Demographic information, including gender, age, resi-
dential area (e.g. large or small city), and socioeconomic
factors, including education, occupation and housingics of study population at the end of therapy by new or
e Previously treated case P-value
) 311 (69.9) <0.001
) 134 (30.1)
) 307 (69.0) 0.180
) 138 (31.0)
) 365 (82.0) 0.701
) 80 (18.0)
2.23) 14.97 (9.67-26.10) <0.001†
) 181 (40.7) <0.001*
61 (13.7)
) 87 (19.6)
50 (11.2)
44 (9.9)
22 (4.9)
) 245 (55.1) 0.001
71 (16.0)
) 129 (29.0)
0.32) 9.67 (6.60-17.83) 0.013†
erruption.
Table 3 Predictors of unfavorable outcome (compared to cure) assessed at the end of therapy (n = 403)†
Variable Univariate Multivariate‡
OR 95% CI OR 95% CI
Gender Female 1 1
Male 1.04 0.57-1.87 0.92 0.42-2.01
Age 20-34 1 1
35-49 1.09 0.64-1.85 1.00 0.48-2.09
≥50 0.70 0.39-1.24 0.78 0.35-1.72
Body Mass Index <18.5 1 -
≥18.5 0.86 0.55-1.34
Diabetes No 1 1
Yes 1.78* 1.07-2.95 2.52** 1.27-5.01
Alcohol, within 6 months Less than once a week 1 1
Several times a week 0.40* 0.19-0.83 0.38* 0.16-0.93
At least once a day 0.59** 0.36-0.98 1.10 0.56-2.19
Smoking, within 6 months Never smoked 1 -
< 1 pack/day 1.11 0.63-1.94
1 pack/day 0.39** 0.21-0.72
> 1 pack/day 0.58 0.30-1.13
Residential area Small city and town 1 -
Large city 1.70* 1.10-2.64
Education High school, above 1 -
Middle school, below or refusal 0.73 0.47-1.15
Occupation Health care, professional and office work 1 -
Service sector and laborer 0.44* 0.23-0.83
Unemployment and others 0.56 0.29-1.08
Chest X-ray
Grade Minimal or moderate 1 -
Far advanced 1.63* 1.05-3.54
Cavity No 1 -
Yes or not clear 1.88* 1.02-3.45
Nodular lesion No 1 -
Yes or not clear 1.48 0.59-3.76
Bilateral Unilateral 1 -
Bilateral 3.45** 1.66-7.19
Number of previous treatment episodes 0 (new case) 1 1
1 2.50* 1.05-5.96 2.38 0.91-6.25
2 5.02*** 2.11-11.93 2.03 0.72-5.79
3 10.27*** 4.05-26.04 3.28* 1.06-10.14
≥4 28.54*** 13.30-61.24 10.30*** 3.79-27.94
History of failure No 1 -
Yes 8.00*** 4.93-12.99
History of TI No 1 -
Yes 2.15** 1.37-3.38
Number of significant regimen changes 0 1 1
≥1 7.26*** 4.53-11.64 4.01*** 2.16-7.44
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Table 3 Predictors of unfavorable outcome (compared to cure) assessed at the end of therapy (n = 403)† (Continued)
Drug susceptibility pattern DS 1 1
Mono/poly-R 2.40 0.93-6.18 0.93 0.31-2.78
Rif, mono-R 2.74 0.53-14.00 0.58 0.07-4.46
MDR 14.18*** 7.47-26.90 2.75* 1.13-6.72
*p <0.05, **p <0.01, ***p < 0.001.
† Favorable outcome is cured (n = 289) and unfavorable outcome includes failure (n = 65) and death (n = 49) assessed at the end of therapy.
‡ Multivariate model includes age, gender and all significant factors from the univariate model.
TI: treatment interruption; DS: Drug susceptible, Mono/poly-R: mono or poly-drug resistance that is not matched with the definition of multidrug-resistant tuberculosis
or rifampin mono resistance; MDR: multidrug-resistant tuberculosis.
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rized into three groups (20-34, 35-49, and ≥50) for the
purposes of analysis. Relevant subject medical history that
was collected included: alcohol consumption, smoking
history, diabetes mellitus status, and previous tuberculosis
treatment history, including drug-susceptibility testing
(DST), elevation of total bilirubin, elevation of liver en-
zymes (alanine aminotransferase and aspartate amino-
transferase) and chest X-ray reports. Korean tuberculosis
guidelines define ‘far advanced’ disease on chest X-ray as
“disseminated lesions of slight to moderate density ex-
ceeding the total volume of one lung or dense and con-
fluent lesions exceeding one third the volume of one
lung or the presence of cavities greater than 4 cm in
diameter” [18]. A significant regimen change was defined
as: i) any change from 1st-line drugs to 2nd-line drugs; ii)
adding either a later generation fluoroquinolone or linezo-
lid to baseline 2nd-line drugs; or iii) adding 2 or more clas-
ses of 2nd-line drugs.
Statistical methods
Comparisons of characteristics between patients who
were new and previously treated were conducted using
the Mann-Whitney test for continuous variables and
Fisher‘s exact test if any value was less than 5 in a cell or
Pearson‘s χ2 test for categorical variables. The first com-
parison was performed to identify factors associated with
unfavorable outcomes (failure or death) versus cure at
EOT using logistic regression. A second comparison was
conducted to identify factors associated with unfavorable
outcomes (failure, death, or relapse) compared to cure at
EOS by binary logistic regression. A third logistic
regression was performed looking at risk factors for
treatment interruptions (relative to those cured). Fi-
nally, Cox proportional hazards regression analysis was
used to identify factors associated with unfavorable
outcomes (death or relapse) at EOS among those cured
at EOT. All multivariate models considered age, gen-
der, and all variables that were univariately significant.
With the exception of age and gender, variables that
were no longer significant in the multivariate model
were dropped. Statistical analyses were performed
with Stata/SE 12.0 (Stata Corp., College Station, TX,USA) with P value < 0.05 as the criterion for statistical
significance.
Ethics
Informed consent was obtained from all participants in
the study. This study was approved by the Institutional
Review Boards of the National Medical Center and the
National Masan Tuberculosis Hospital in South Korea,
and the National Institute of Allergy and Infectious Dis-
eases in the U.S. This study was conducted in accordance
with ICH-GCP and monitored by an independent clinical
research organization.
Results
Baseline and treatment characteristics
A total of 669 patients were enrolled in the study from
2005-2012, 563 (84.2%) of whom were male with a me-
dian age of 44 years. Except for smoking history and
tuberculosis-related clinical factors, there were no sig-
nificant differences in baseline characteristics between
new and previously treated cases. Compared with new
cases, previously treated patients presented with similar
sputum smear scores but significantly more advanced
and bilateral disease on baseline chest X-ray and more
drug resistance (Table 1).
By EOT, the previously treated group experienced sig-
nificantly more regimen changes. Previously treated cases
had lower proportions of cured and higher proportions of
failed, unknown outcomes, and deaths compared to new
cases (Table 2).
Predictors of unfavorable outcomes at the end of treatment
Among the 403 patients with complete information
available at EOT, 289 (71.7%) were cured, 65 failed, and
49 died. The multivariate analysis of baseline risk factors
associated with unfavorable outcomes (failure or death)
at EOT included diabetes (OR = 2.52; 95% CI = 1.27-
5.01), patients drinking several times a week (OR = 0.38:
95% CI = 0.16-0.93, compared to drinking less than once
a week), ≥1 significant regimen changes (OR = 4.01; 95%
CI = 2.16-7.44), MDR-TB (OR = 2.75; 95%CI = 1.13-6.72,
compared to drug-sensitive TB), and patients with 3
or ≥4 previous treatment episodes (OR = 3.28; 95% CI =
Table 4 Predictors of unfavorable outcome (compared to cure) assessed at the end of study (n = 392) †
Variable Univariate Multivariate‡
OR 95% CI OR 95% CI
Gender Female 1 1
Male 1.29 0.70-2.35 1.14 0.59-2.20
Age 20-34 1 1
35-49 1.96* 1.07-3.57 2.14* 1.11-4.14
≥50 2.75** 1.50-5.05 2.97** 1.51-5.86
Body Mass Index <18.5 1 1
≥18.5 0.47** 0.31-0.73 0.33*** 0.20-0.54
Diabetes No 1 1
Yes 2.47*** 1.51-4.05 2.57** 1.46-4.52
Alcohol, within 6 months Less than once a week 1 -
Several times a week 0.52 0.26-1.05
At least once a day 0.92 0.58-1.48
Smoking, within 6 months Never smoked 1 -
< 1 pack/day 1.71 0.99-2.97
1 pack/day 1.14 0.66-1.97
> 1 pack/day 1.03 0.57-1.89
Residence Small city and town 1 -
Large city 1.19 0.78-1.83
Education High school, above 1 -
Middle school, below or refusal 1.40 0.92-2.15
Occupation Health care, professional and office work 1 -
Service sector and laborer 1.35 0.66-2.76
Unemployment and others 1.54 0.73-3.24
Chest X-ray
Grade Minimal or moderate 1 -
Far advanced 2.09** 1.35-3.24
Cavity No 1 -
Yes or not clear 1.25 0.72-2.15
Nodular lesion No 1 -
Yes or not clear 1.44 0.60-3.48
Bilateral Unilateral 1 -
Bilateral 2.67** 1.38-5.18
Number of previous treatment episodes 0 (new case) 1 -
1 1.7 0.90-3.22
2 1.04 0.48-2.27
≥3 4.66*** 2.69-8.08
History of failure No 1 -
Yes 3.32*** 2.11-5.22
History of TI No 1 -
Yes 2.26*** 1.45-3.51
Number of significant regimen changes 0 1 -
≥1 1.21 0.75-1.93
Drug Susceptibility pattern (n = 401) DS 1 1
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Table 4 Predictors of unfavorable outcome (compared to cure) assessed at the end of study (n = 392) † (Continued)
Mono/poly-R 1.42 0.68-2.97 1.45 0.67-3.13
Rif, mono-R 1.69 0.42-6.87 2.87 0.64-12.95
MDR 3.39*** 2.09-5.50 4.51*** 2.64-7.68
*p <0.05, **p <0.01, ***p < 0.001.
† Favorable outcome is cured (n = 267) and unfavorable outcome includes failure (n = 22), death (n = 86) and relapse (n = 17) assessed at the end of study.
‡ Multivariate model includes age, gender and all significant factors from the univariate model.
TI: treatment interruption; DS: Drug susceptible, Mono/poly-R: mono or poly-drug resistance that is not matched with the definition of multidrug-resistant
tuberculosis or rifampin mono resistance; MDR: multidrug-resistant tuberculosis.
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spectively, compared to no previous treatment episodes)
(Table 3). The presence of cavities or bilateral lesions on
chest x-ray and having one or more previous treatment
failures were significantly associated with unfavorable
outcomes in the univariate analysis but not in the multi-
variate analysis.
Long-term predictors of unfavorable outcomes at the
end of study
Among the 392 patients followed to EOS (40 months
after EOT), 267 (67.6%) were considered cures, 22 failed,
17 relapsed, and 86 died. The multivariate analysis of
baseline risk factors associated with unfavorable outcomes
(failure, relapse, or death) at EOS included age 35-49 or
age ≥50 (OR = 2.14; 95% CI = 1.11-4.14 and OR = 2.97;
95% CI = 1.51-5.86, respectively, compared to those age
20-34), diabetes (OR = 2.57; 95% CI = 1.46-4.52), and
having MDR-TB (OR = 4.51, 95% CI = 2.64-7.68, com-
pared to drug sensitive TB) (Table 4). Having a body-mass
index (BMI) ≥18.5 was associated with cure (OR = 0.33;
95% CI = 0.20-0.54, compared to BMI <18.5). Baseline
chest x-ray status and previous treatment history were sig-
nificantly associated with unfavorable outcomes in the
univariate analysis but not in the multivariate analysis.
Predictors of treatment interruption (TI) at the end
of therapy
Among the total 457 patients with full information at
EOT, 335 were cured and 122 experienced a TI. In the
multivariate analysis compared with those who were
cured, those with a TI were significantly more likely to
work in the service sector or as a laborer (OR = 2.30;
95% CI = 1.36-3.90, compared with those unemployed),
present with bilateral lesions on chest X-ray (OR = 2.46;
95% CI = 1.22-4.95), or have a previous treatment failure
(OR = 1.76; 95% CI = 1.04-2.98) or previous TI (OR = 2.35;
95% CI = 1.49-3.70) (Table 5).
Long-term prognosis of cured cases at the end of therapy
Among the total 289 cured cases with full information
at EOT, 278 (96.2%) cases had full follow-up information
to EOS. After treatment completion, there were 20 deaths
and 17 relapse cases with full baseline and follow-upinformation. Age ≥50, BMI and education were associated
with death or relapse in univariate analysis. In the multi-
variate analysis, the factors that remained significant were
age ≥50 (OR = 3.11; 95% CI = 1.17-8.26, compared to
those age 20-34) and BMI ≥18.5 being associated with
cure (HR = 0.49; 95% CI = 0.25-0.95). Having MDR-TB at
baseline was not a significant prognostic factor in univari-
ate analysis (HR = 0.87; 95% CI = 0.40-1.89; not shown in
table) (Table 6).
Discussion
Multiple previous cohort studies have reported exten-
sively on the risk factors of tuberculosis outcomes, using
various measures including relapse [15,16], mortality
[7,10,14,19], MDR or XDR-TB status [11,13,20], and
treatment failure, TI, or death [12,21,22]. In addition, dif-
fering study end points were used, including the end of
therapy [12,21,22], long term follow up after treatment
completion [14-16], and cross-sectional comparison be-
tween M/XDR and potential risk factors [11,13,20]. Our
study identified factors associated with poor outcomes
among all patients at EOT and after long-term follow-up
at EOS. In addition, in an effort to separate EOS risk fac-
tors from EOT risk factors, an analysis was done to iden-
tify factors for relapse or death at EOS just among those
considered cured at EOT. At EOT, having diabetes, ≥3 pre-
vious treatment episodes, ≥1 significant regimen changes,
and MDR-TB were all significantly associated with treat-
ment failure or death (Table 3). At EOS, having diabetes
and MDR-TB at baseline continued to be significantly asso-
ciated with treatment failure, death, or relapse. In addition,
baseline age ≥35 and BMI <18.5 were also poor prognostic
factors, but the number of previous treatment episodes was
no longer significant (Table 4). These risk factors, including
age, BMI, and drug resistance pattern, are consistent with
those of a previous study with long-term follow-up [14].
These results may suggest that older age and low BMI
contribute to relapse or death risk after treatment comple-
tion. In isolating risk factors significantly associated with
poor outcomes at EOS among cures at EOT, only age ≥50
and baseline BMI <18.5 were identified (Table 6), suggest-
ing that once a patient is cured, many traditional baseline
predictive variables, such as chest x-ray status, previous
TB treatment history, and MDR-TB status may no longer
Table 5 Predictors of treatment interruption (compared to cures) (n = 457) †
Variable Univariate Multivariate‡
OR 95% CI OR 95% CI
Gender Female 1 1
Male 1.48 0.79-2.78 1.53 0.78-3.00
Age 20-34 1 1
35-49 1.16 0.69-1.95 0.92 0.53-1.59
≥50 0.67 0.38-1.18 0.63 0.34-1.16
Body Mass Index (n = 446) <18.5 1 -
≥18.5 0.78 0.51-1.91
Diabetes No 1 -
Yes 1.56 0.95-2.56
Alcohol, within 6 months Less than once a week 1 -
Several times a week 1.71 0.96-3.05
At least once a day 2.03** 1.27-3.24
Smoking, within 6 months Never smoked 1 -
< 1 pack/day 2.68** 1.31-5.49
1 pack/day 3.36*** 1.75-6.46
> 1 pack/day 3.12** 1.54-6.32
Residence Small city and town 1 -
Large city 1.20 0.79-1.83
Education High school, above 1 -
Middle school, below or refusal 1.20 0.80-1.82
Occupation Unemployment and others 1 1
Health care, professional and office work 1.14 0.47-2.75 0.89 0.35-2.25
Service sector and laborer 2.39** 1.45-3.95 2.30** 1.36-3.90
Chest X-ray
Grade Minimal or moderate 1 -
Far advanced 1.34 0.89-2.04
Cavity No 1 -
Yes or not clear 1.04 0.63-1.69
Nodular lesion No 1 -
Yes or not clear 2.07 0.70-6.14
Bilateral Unilateral 1 1
Bilateral 2.86** 1.46-5.60 2.46* 1.22-4.95
Number of previous treatment episode 0 (new case) 1 -
1 1.54 0.87-2.71
2 2.77** 1.53-5.02
≥3 2.40** 1.35-4.27
History of failure No 1 1
Yes 1.81* 1.12-2.92 1.76* 1.04-2.98
History of TI No 1 1
Yes 2.72*** 1.77-4.18 2.35*** 1.49-3.70
Elevation of total bilirubin No 1
Yes 0.63* 0.40-1.00
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Table 5 Predictors of treatment interruption (compared to cures) (n = 457) † (Continued)
Elevation of liver enzyme No 1
Yes 0.95 0.55-1.65
Number of significant regimen changes 0 1 -
≥1 1.62* 1.04-2.55
Drug susceptibility pattern (n = 403) DS 1 -
Mono/poly-R 1.25 0.66-2.39
Rif, mono-R 2.01 0.68-5.92
MDR 1.45 0.88-2.39
*p <0.05, **p <0.01, ***p < 0.001.
†Treatment interruption (n = 122) was compared with cured (n = 335).
‡Multivariate model includes age, gender and all significant factors from the univariate model.
TI: Treatment interruption, DS: Drug susceptible, Mono/poly-R: mono or poly-drug resistance that is not matched with the definition of multidrug-resistant
tuberculosis or rifampin mono resistance; MDR: multidrug-resistant tuberculosis.
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factors for TB recurrence at EOS after a median 4-year
follow-up after EOT and identified inner-city residence,
HIV infection, and history of TB treatment as risk factors
[16]. This study, however, included all treatment-
completed patients at EOT regardless of culture conver-
sion status and thus included some patients not fully
cured. Future relapse studies among cured patients should
be conducted to understand if their risk factors revert
back to those similar to the general population.
Some previous studies included TI as an unfavorable
outcome (24-26). Because our study population had a
relatively high proportion of TI (18.2%) and reasons for
TI may be very different from reasons for failure, death, or
relapse, we analyzed this outcome separately, comparing
TI cases only to cured cases. Other studies have alsoTable 6 Prognostic factors of unfavorable outcome at end
of study among cured cases (n = 278) †
Adjusted HR‡ 95% CI
Age
20-34 1
35-49 1.38 0.48-3.98
≥50 3.11* 1.17-8.26
Gender
Female 1
Male 1.14 0.44-2.95
Body Mass Index
<18.5 1
≥18.5 0.49* 0.25-0.95
*p <0.05.
†Among cases who had full information at the end of study, cured cases
(n = 241) were compared with death (n = 20) and relapse (n = 17) cases.
‡Multivariate model includes age, gender and all significant factors from the
univariate model (omitted in this paper).
TI: Treatment interruption, DS: Drug susceptible, Mono/poly/Rif-R: mono or
poly-drug resistance that is not matched with the definition of
multidrug-resistant tuberculosis; MDR: multidrug-resistant tuberculosis.identified risk factors associated specifically with treat-
ment default, including long distance to health facilities,
substance use including alcohol consumption, a fear of so-
cial stigmatism, unemployment and economic constraint
[10,19,23-25]. In our analysis, alcohol consumption and
smoking history were associated with TI in the univariate
analysis but the significance was lost in the multivariate
analysis. Not surprisingly, our study also identified an
increased risk for TI among those who previously had a
TI or treatment failure. For unclear reasons, having bi-
lateral disease on baseline chest x-ray was associated
with TI. Finally, being a blue-collar worker was also risk
factor for TI, compared to those who were unemployed.
This suggests that perhaps low wage workers had more
difficulty getting time off for medical care and may
require healthcare policy changes to resolve this issue.
Further studies may need to be done to understand bet-
ter the reasons for TI among service sector employees
and laborers. Understanding the causes of TI and how
to reduce treatment default is critically important because
of the association of TI with the development of drug
resistance [26].
Our study has several limitations. First, the study was
conducted at two tertiary referral hospitals, which usually
manage patients with more severe and extensive disease.
This is reflected in our cohort demographics, with most
patients having more severe advanced disease on x-ray, in-
cluding cavities and bilateral disease, as well as the propor-
tion of previously treated cases (compared to new cases)
and MDR-TB. Our results, therefore, may not be repre-
sentative of patients with less severe disease. Second, we
only had DST results for 581/669 (86.8%). Analyses that
include DST results exclude patients without DST results,
which may cause a selection bias and the point estimates
may be over or under-estimated due to the excluded cases.
Third, we were not able to measure certain factors pos-
sibly related to treatment outcome, including hemoglobin
A1c and bacterial load (time to positivity in liquid culture
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and types I vs. II could not be differentiated. Finally,
the study was not designed to identify a causal pathway
between the independent and outcome variables and
was limited to identifying factors associated with unfavor-
able outcomes and TI.
Conclusions
This study of risk factors associated with poor treatment
outcomes at EOT and EOS highlights both patient spe-
cific factors that are difficult to change, such as diabetes
status and age, as well as disease specific factors, such as
multidrug resistance, that may be affected by program-
matic factors and could be altered to improve prognosis.
Risk factors related to prolonged disease at diagnosis, in-
cluding history of multiple previous treatment episodes,
emphasize that the initial treatment episode is also likely
the best chance of cure. Program management changes
should be considered to emphasize public health measures
such as directly observed therapy to help ensure that the
first treatment episode is also the last one, in conjunction
with improving adherence and decreasing the risk of
MDR-TB. Policy changes to enable all TB patients, regard-
less of work status, to have time off to get appropriate
treatment would also be important. Finally, steps to im-
prove nutrition and therefore BMI among those success-
fully treated may help prevent longer-term relapses or
recurrences. The treatment of tuberculosis requires a
multifaceted approach for the best chance of success.
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